Difference between revisions of "Autoimmune cytopenia"
Jump to navigation
Jump to search
(Created page with "'''Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer.''' Is...") |
Warner-admin (talk | contribs) m (Text replacement - "'''contains dosing details in abstract'''" to "'''dosing details in abstract have been reviewed by our editors'''") |
||
(79 intermediate revisions by 4 users not shown) | |||
Line 1: | Line 1: | ||
− | ''' | + | <span id="BackToTop"></span> |
− | + | <div class="noprint" style="background-color:LightGray; position:fixed; bottom:2%; right:0.25%; padding-left:5px; padding-right:5px; margin: 15px; opacity:0.8; border-style: solid; border-color:DarkGray; border-width: 1px"> | |
− | + | [[#top|Back to Top]] | |
− | + | </div> | |
+ | {{#lst:Editorial board transclusions|heme}} | ||
+ | ''This is an umbrella category that includes Felty's syndrome (autoimmune neutropenia), [[#Autoimmune_thrombocytopenic_purpura_(ITP)|autoimmune thrombocytopenia (ITP)]], [[autoimmune hemolytic anemia (AIHA)]], and Evan's syndrome (AIHA & ITP). Please see the respective page(s) for disease-specific therapies. This page includes regimens that were used more broadly.'' | ||
+ | *''We have moved [[How I Treat]] articles to a dedicated page.'' | ||
{| class="wikitable" style="float:right; margin-right: 5px;" | {| class="wikitable" style="float:right; margin-right: 5px;" | ||
|- | |- | ||
− | |<div style="background-color: # | + | |<div style="background-color: #fee0d1; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}" align="right"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Regimen |limit=10000|format=sum}} [[Tutorial#Regimens|regimens]] on this page</b></font></div> |
− | <div style="background-color: # | + | <div style="background-color: #deebf6; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Variant |limit=10000|format=sum}} [[Tutorial#Variants|variants]] on this page</b></font></div> |
|} | |} | ||
{{TOC limit|limit=3}} | {{TOC limit|limit=3}} | ||
− | + | =Relapsed or refractory= | |
− | + | ==Alemtuzumab monotherapy {{#subobject:34416b|Regimen=1}}== | |
− | + | <div class="toccolours" style="background-color:#eeeeee"> | |
− | = | + | ===Regimen {{#subobject:#30ab57|Variant=1}}=== |
− | + | {| class="wikitable sortable" style="width: 80%; text-align:center;" | |
− | == | + | !style="width: 25%"|Study |
− | {| class="wikitable" style=" | + | !style="width: 25%"|Dates of enrollment |
+ | !style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
+ | !style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]] | ||
+ | |- | ||
+ | |[https://doi.org/10.1046/j.1365-2141.2001.03039.x Willis et al. 2001] | ||
+ | |1995-11 to 2000-08 | ||
+ | |style="background-color:#91cf61"|Phase 2 | ||
+ | |style="background-color:#b5b5b5"|ORR: 71% | ||
|- | |- | ||
− | |||
|} | |} | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
+ | ====Immunosuppressive therapy==== | ||
+ | *[[Alemtuzumab (Campath)]] as follows: | ||
+ | **Test dose: 1 mg IV over 60 minutes once | ||
+ | **Days 1 to 10: 10 mg IV over 4 hours once per day | ||
+ | '''10-day course''' | ||
+ | </div></div> | ||
+ | ===References=== | ||
+ | # Willis F, Marsh JC, Bevan DH, Killick SB, Lucas G, Griffiths R, Ouwehand W, Hale G, Waldmann H, Gordon-Smith EC. The effect of treatment with Campath-1H in patients with autoimmune cytopenias. Br J Haematol. 2001 Sep;114(4):891-8. [https://doi.org/10.1046/j.1365-2141.2001.03039.x link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/11564082/ PubMed] | ||
+ | ==Sirolimus monotherapy {{#subobject:35516b|Regimen=1}}== | ||
+ | <div class="toccolours" style="background-color:#eeeeee"> | ||
===Regimen {{#subobject:#41ab57|Variant=1}}=== | ===Regimen {{#subobject:#41ab57|Variant=1}}=== | ||
− | {| | + | {| class="wikitable sortable" style="width: 80%; text-align:center;" |
− | | | + | !style="width: 25%"|Study |
− | |[[Levels_of_Evidence#Evidence| | + | !style="width: 25%"|Dates of enrollment |
+ | !style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
+ | !style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]] | ||
|- | |- | ||
− | |[ | + | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4705607/ Bride et al. 2015] |
− | | | + | |Not reported |
− | style="background:# | + | |style="background-color:#91cf61"|Phase 2 |
− | + | | style="background-color:#91cf60" |Durable CR observed in patients with ALPS | |
− | |||
− | |||
− | |||
|- | |- | ||
|} | |} | ||
− | + | <div class="toccolours" style="background-color:#b3e2cd"> | |
− | *[[Sirolimus (Rapamune)]] 2 | + | ====Immunosuppressive therapy==== |
− | + | *[[Sirolimus (Rapamune)]] 2 to 2.5 mg/m<sup>2</sup>/day PO | |
− | |||
'''6-month course, extended for those with a favorable response''' | '''6-month course, extended for those with a favorable response''' | ||
− | + | </div> | |
+ | <div class="toccolours" style="background-color:#fff2ae"> | ||
+ | ====Dose and schedule modifications==== | ||
+ | *See manuscript for recommended dose adjustments | ||
+ | </div></div> | ||
===References=== | ===References=== | ||
− | # Bride KL, Vincent T, Smith-Whitley K, Lambert MP, Bleesing JJ, Seif AE, Manno CS, Casper J, Grupp SA, Teachey DT. Sirolimus is effective in relapsed/refractory autoimmune cytopenias: results of a prospective multi-institutional trial. Blood. 2016 Jan 7;127(1):17-28. Epub 2015 Oct 26. [ | + | # Bride KL, Vincent T, Smith-Whitley K, Lambert MP, Bleesing JJ, Seif AE, Manno CS, Casper J, Grupp SA, Teachey DT. Sirolimus is effective in relapsed/refractory autoimmune cytopenias: results of a prospective multi-institutional trial. Blood. 2016 Jan 7;127(1):17-28. Epub 2015 Oct 26. [https://doi.org/10.1182/blood-2015-07-657981 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4705607/ link to PMC article] '''dosing details in abstract have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/26504182/ PubMed] [https://clinicaltrials.gov/study/NCT00392951 NCT00392951] |
+ | [[Category:Autoimmune cytopenia regimens]] | ||
+ | [[Category:Disease-specific pages]] | ||
+ | [[Category:Autoimmune hematologic conditions]] | ||
+ | [[Category:Hemolytic process]] | ||
+ | [[Category:Cytopenias]] |
Latest revision as of 23:40, 15 July 2024
Section editor | |
---|---|
Benjamin Tillman, MD Vanderbilt University Nashville, TN, USA |
This is an umbrella category that includes Felty's syndrome (autoimmune neutropenia), autoimmune thrombocytopenia (ITP), autoimmune hemolytic anemia (AIHA), and Evan's syndrome (AIHA & ITP). Please see the respective page(s) for disease-specific therapies. This page includes regimens that were used more broadly.
- We have moved How I Treat articles to a dedicated page.
2 regimens on this page
2 variants on this page
|
Relapsed or refractory
Alemtuzumab monotherapy
Regimen
Study | Dates of enrollment | Evidence | Efficacy |
---|---|---|---|
Willis et al. 2001 | 1995-11 to 2000-08 | Phase 2 | ORR: 71% |
Immunosuppressive therapy
- Alemtuzumab (Campath) as follows:
- Test dose: 1 mg IV over 60 minutes once
- Days 1 to 10: 10 mg IV over 4 hours once per day
10-day course
References
- Willis F, Marsh JC, Bevan DH, Killick SB, Lucas G, Griffiths R, Ouwehand W, Hale G, Waldmann H, Gordon-Smith EC. The effect of treatment with Campath-1H in patients with autoimmune cytopenias. Br J Haematol. 2001 Sep;114(4):891-8. link to original article dosing details in manuscript have been reviewed by our editors PubMed
Sirolimus monotherapy
Regimen
Study | Dates of enrollment | Evidence | Efficacy |
---|---|---|---|
Bride et al. 2015 | Not reported | Phase 2 | Durable CR observed in patients with ALPS |
Immunosuppressive therapy
- Sirolimus (Rapamune) 2 to 2.5 mg/m2/day PO
6-month course, extended for those with a favorable response
Dose and schedule modifications
- See manuscript for recommended dose adjustments
References
- Bride KL, Vincent T, Smith-Whitley K, Lambert MP, Bleesing JJ, Seif AE, Manno CS, Casper J, Grupp SA, Teachey DT. Sirolimus is effective in relapsed/refractory autoimmune cytopenias: results of a prospective multi-institutional trial. Blood. 2016 Jan 7;127(1):17-28. Epub 2015 Oct 26. link to original article link to PMC article dosing details in abstract have been reviewed by our editors PubMed NCT00392951